**Background:** This document presents a compilation of abstracts from the combined 77th Brazilian Congress of Cardiology and the World Congress of Cardiology, held in October 2022. The abstracts cover a broad spectrum of cardiovascular medicine, including epidemiology, heart failure, neglected diseases (particularly Chagas cardiomyopathy), coronary artery disease, and the impact of COVID-19. The collection features original research, case reports, and systematic reviews from researchers worldwide, with a significant representation from Latin America.
**Methods:** The abstracts describe a variety of study designs. These include prospective cohort studies (e.g., the 3-year follow-up of Chagas heart failure patients by Mansur et al., and the BREATHE registry), ecological time-series studies (e.g., the relationship between sociodemographic index and ischemic heart disease in Brazil by Bichara et al.), systematic reviews and meta-analyses (e.g., the effectiveness of influenza vaccination by Barbetta et al.), randomized controlled trials (e.g., exercise training in cardio-oncology patients by Rodriguez et al.), and experimental animal studies (e.g., myocardial perfusion in Chagas by Tanaka et al.). Data sources include national registries (DATASUS), international surveys, and single-center patient cohorts.
**Key Results:** Several key findings emerge from these abstracts. In Chagas cardiomyopathy, Mansur et al. (107880) found that over a 3-year follow-up, 44% of men and 36% of women died (log-rank p=0.002), with women having a better prognosis. Predictors of death included diabetes, previous stroke, and chronic kidney disease. The BREATHE registry (Simões et al., 110777) showed that patients hospitalized with acute heart failure due to Chagas cardiomyopathy had a significantly higher 12-month mortality (40.8% vs. 27.8%, p<0.001) compared to other etiologies, with an odds ratio of 2.02. Regarding ischemic heart disease, Bichara et al. (108498) reported that Brazil's age-standardized mortality rate for IHD decreased from 46.12 to 36.42 per 100,000 inhabitants between 2000 and 2019, correlating with an improving sociodemographic index. Barbetta et al. (109929) found in their meta-analysis that influenza vaccination reduced all-cause mortality (RR 0.50, CI 0.29-0.88, p=0.02) and cardiovascular mortality (RR 0.54, CI 0.37-0.80, p=0.002) in patients with coronary artery disease. The impact of COVID-19 was also assessed; Brant et al. (108346) reported a 16% reduction in hospitalizations for cardiovascular diseases during the pandemic, but with a higher proportion of in-hospital deaths (RiR 1.14).
**Clinical Implications:** The findings have several important clinical implications. The consistent data on Chagas cardiomyopathy underscore the need for aggressive management of comorbidities like diabetes and CKD, and highlight the higher risk in men. The benefit of influenza vaccination as a secondary prevention strategy for CAD, particularly after acute coronary syndrome, supports its wider implementation. The disruption of cardiovascular care during the COVID-19 pandemic, evidenced by reduced hospitalizations and increased mortality, emphasizes the need for resilient healthcare systems and public health campaigns to ensure timely care during future health crises. The studies on exercise training in various populations (aortic stenosis, cardio-oncology) suggest non-pharmacological interventions can improve cardiac function and quality of life.